Combining retinoic acid and oral arsenic may be potentially the first-line therapy for non-high-risk acute promyelocytic leukemia

Affiliations

¹ Department of Hematology and Lymphoma Research Center, Peking University, Third Hospital, Beijing 100191, China;; Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China.
² Department of Biomedical Engineering, Chinese PLA General Hospital, Beijing 100853, China.
³ Department of Hematology and Lymphoma Research Center, Peking University, Third Hospital, Beijing 100191, China.
⁴ Department of Hematology, Chinese PLA General Hospital, Beijing 100853, China.
⁵ Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China.

Comment

Lin Fu et al. Stem Cell Investig. 2016.

. 2016 Dec 19:3:93.

doi: 10.21037/sci.2016.11.13. eCollection 2016.

¹ Department of Hematology and Lymphoma Research Center, Peking University, Third Hospital, Beijing 100191, China;; Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China.
² Department of Biomedical Engineering, Chinese PLA General Hospital, Beijing 100853, China.
³ Department of Hematology and Lymphoma Research Center, Peking University, Third Hospital, Beijing 100191, China.
⁴ Department of Hematology, Chinese PLA General Hospital, Beijing 100853, China.
⁵ Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China.

No abstract available

Conflict of interest statement

The authors have no conflicts of interest to declare.

Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial.
Platzbecker U, Avvisati G, Cicconi L, Thiede C, Paoloni F, Vignetti M, Ferrara F, Divona M, Albano F, Efficace F, Fazi P, Sborgia M, Di Bona E, Breccia M, Borlenghi E, Cairoli R, Rambaldi A, Melillo L, La Nasa G, Fiedler W, Brossart P, Hertenstein B, Salih HR, Wattad M, Lübbert M, Brandts CH, Hänel M, Röllig C, Schmitz N, Link H, Frairia C, Pogliani EM, Fozza C, D'Arco AM, Di Renzo N, Cortelezzi A, Fabbiano F, Döhner K, Ganser A, Döhner H, Amadori S, Mandelli F, Ehninger G, Schlenk RF, Lo-Coco F. Platzbecker U, et al. J Clin Oncol. 2017 Feb 20;35(6):605-612. doi: 10.1200/JCO.2016.67.1982. Epub 2016 Oct 31. J Clin Oncol. 2017. PMID: 27400939 Clinical Trial.

1. Lo-Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 2013;369:111-21. 10.1056/NEJMoa1300874 - DOI - PubMed
1. Platzbecker U, Avvisati G, Cicconi L, et al. Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial. J Clin Oncol 2016. [Epub ahead of print]. 10.1200/JCO.2016.67.1982 - DOI - PubMed
1. Iland HJ, Collins M, Bradstock K, et al. Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial. Lancet Haematol 2015;2:e357-66. 10.1016/S2352-3026(15)00115-5 - DOI - PubMed
1. Efficace F, Mandelli F, Avvisati G, et al. Randomized phase III trial of retinoic acid and arsenic trioxide versus retinoic acid and chemotherapy in patients with acute promyelocytic leukemia: health-related quality-of-life outcomes. J Clin Oncol 2014;32:3406-12. 10.1200/JCO.2014.55.3453 - DOI - PubMed
1. Rahman A. Quality of life with treated acute promyelocytic leukaemia. Lancet Oncol 2014;15:e533. 10.1016/S1470-2045(14)70494-2 - DOI - PubMed